Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases.
Journal Article (Journal Article)
BACKGROUND: Early experiments using ligand-binding assays demonstrated the presence of estrogen receptor (ER) in fibromatoses. These findings were not confirmed by later studies using immunohistochemical analysis. METHODS: To verify the expression of ERs in fibromatosis as well as to clarify the inconsistency between radioligand and early immunohistochemical studies, the authors examined a series of 40 extraabdominal fibromatoses using antibodies raised against ERbeta. RESULTS: All 40 cases of extraabdominal fibromatosis were at least focally positive for ERbeta. Thirty-three of 40 (83%) displayed 3+ (>50%) expression, 5 of 40 (12%) were 2+ (11-50%), and 2 of 40 (5%) cases showed 1+ (<10%) expression. All cases were negative for ERalpha. CONCLUSIONS: Although extraabdominal fibromatosis does not express ERalpha, there appears to be nearly uniform expression of ERbeta. This finding clarifies discrepancies in the literature regarding estrogen expression in fibromatosis, and provides a biological mechanism for the action of antiestrogenic compounds in the treatment of fibromatosis. Estrogen antagonists may have a role in the treatment of refractory or recurrent extraabdominal fibromatoses.
Full Text
Duke Authors
Cited Authors
- Deyrup, AT; Tretiakova, M; Montag, AG
Published Date
- January 1, 2006
Published In
Volume / Issue
- 106 / 1
Start / End Page
- 208 - 213
PubMed ID
- 16333857
International Standard Serial Number (ISSN)
- 0008-543X
Digital Object Identifier (DOI)
- 10.1002/cncr.21553
Language
- eng
Conference Location
- United States